Syndax Pharmaceuticals (SNDX) Consolidated Net Income (2015 - 2026)

Syndax Pharmaceuticals' Consolidated Net Income history runs 12 years deep, the most recent figure standing at -$30.6 million for Q1 2026.

• In Q1 2026, Consolidated Net Income rose 59.99% year-over-year to -$30.6 million; the TTM figure through Mar 2026 stood at -$204.4 million (up 35.68% YoY), while the FY2025 annual figure was -$250.4 million, up 20.16% from the prior year.
• Consolidated Net Income was -$30.6 million for Q1 2026 at Syndax Pharmaceuticals, up from -$58.2 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of -$30.6 million in Q1 2026 to a low of -$89.1 million in Q4 2024.
• Historically, Consolidated Net Income has averaged -$56.0 million across 5 years, with a median of -$52.2 million in 2025.
• The sharpest annual moves came in 2022 and 2026: Consolidated Net Income sank 140.78% in 2022, then surged 59.99% in 2026.
• A 5-year view of Consolidated Net Income shows it stood at -$39.1 million in 2022, then tumbled by 85.27% to -$72.4 million in 2023, then slipped by 23.08% to -$89.1 million in 2024, then soared by 34.68% to -$58.2 million in 2025, then soared by 47.37% to -$30.6 million in 2026.
• The last three Consolidated Net Income figures came in at -$30.6 million (Q1 2026), -$58.2 million (Q4 2025), and -$52.2 million (Q3 2025), per Business Quant data.